dacomitinib

Dacomitinib (trade name Vizimpro) is a drug candidate under development by Pfizer for the treatment of non-small-cell lung carcinoma (NSCLC). It is a selective and irreversible inhibitor of EGFR.[1] Dacomitinib has advanced to several Phase III clinical trials. The Jan 2014 results of the first trials were disappointing, with a

Metabolism: CYP2D6, CYP3A4

VIZIMPRO ® (dacomitinib) is a prescription medicine used to treat non-small cell lung cancer (NSCLC) that has spread to other parts of the body (metastatic). VIZIMPRO is used as a first treatment if your tumor has certain types of abnormal epidermal growth factor

Dacomitinib | C24H25ClFN5O2 | CID 11511120 – structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities

达克替尼 (Dacomitinib,PF-00299804)是是美国辉瑞公司研发的一种第二代、不可逆、表皮生长因子(EGFR)酪氨酸激酶抑制剂(TKI),达克替尼是一种泛HER抑制剂,而且入脑效果较好。其靶点不仅有EGFR(HER1),而且还有HER2和HER4,也可能因为

 · PDF 檔案

A7471027: A multicenter trial of dacomitinib as a first-line treatment in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.7 – Complete For a complete listing of dacomitinib clinical trials, please visit www.clinicaltrials.gov.

Dacomitinib 於非小細胞肺癌的進展 【文: 中西結合癌症治療 腫瘤 / 安寧療護西醫專科醫師 癌症中西醫師 陳駿逸】 輝瑞藥廠所研發的 Dacomitinib 是一種口服、強效和具有選擇性的小分子酪氨酸激酶抑制劑,不可逆地抑制 HER1/EGFR、HER2、HER4 的激酶活性

生物活性 达克替尼(Dacomitinib,PF299804)是一种有效的,不可逆的pan-ErbB抑制剂,最有效作用于EGFR,IC50为6 nM,高效作用于携带EGFR或ERBB2突变型(抗Gefitinib)和携带EGFR T790M突变型的NSCLCs。Phase 2。

 · PDF 檔案

Dacomitinib is an investigational, oral, once-daily, irreversible pan-human epidermal growth factor receptor (HER) tyrosine kinase inhibitor. It has not received regulatory approval in any country. Worldwide, lung cancer is the leading cause of cancer death in both1

Dacomitinib (10 mg/kg/d by daily oral gavage) effectively inhibits the growth of HCC827 GFP xenografts. In contrast, HCC827 Del/T790M xenografts are resistant to Gefitinib, whereas Dacomitinib treatment is substantially more effective at inhibiting growth of this .

品牌: MCE

Dacomitinib was tested using a series of genetic toxicology assays. Dacomitinib was not mutagenic in a bacterial reverse mutation (Ames) assay, and not clastogenic or aneugenic in the in vivo bone marrow micronucleus assay in male and female rats.

Dacomitinib is used to treat non-small cell lung cancer that has spread to other parts of the body. Dacomitinib is given only if your tumor has a specific genetic marker (an abnormal “EGFR” gene). Dacomitinib may also be used for purposes not listed in this

Two treatment-related deaths occurred in the dacomitinib group (one related to untreated diarrhoea and one to untreated cholelithases/liver disease) and one in the gefitinib group (related to sigmoid colon diverticulitis/rupture complicated by pneumonia).

14/12/2018 · On Sept. 27, 2018, the Food and Drug Administration approved dacomitinib tablets (VIZIMPRO, Pfizer Pharmaceutical Company) for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19

Dacomitinib (PF-00299804) is an investigative oral treatment for non-small cell lung cancer (NSCLC), currently being developed by Pfizer. How dacomitinib works Dacomitinib is part of a class of drugs called tyrosine-kinase inhibitors (TKIs).

Dacomitinib is approved to treat: Non-small cell lung cancer (NSCLC) that has metastasized (spread to other parts of the body). It is used as first-line treatment in patients whose tumors have certain EGFR gene mutations. Dacomitinib is also being.

10/10/2019 · 之前睇過d 報道Dacomitinib 已做實驗,唔知而家註冊未? 如果azd9291 耐藥後食佢得唔得今日見過莫教授話AZD 9291後都係用A+C化, 呢隻D藥用於第二代之後 [本帖最後由 josie725 於

14/8/2019 · Evidence-based recommendations on dacomitinib (Vizimpro) for untreated locally advanced or metastatic epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer in adults. The recommendations in this guidance represent the view of NICE, arrived at after careful

Dacomitinib (PF299804, PF299)是一种有效的,不可逆的泛ErbB抑制剂,最有效作用于EGFR,无细胞试验中IC50为6 nM,高效作用于携带EGFR或ERBB2突变型(耐Gefitinib)和携带EGFR T790M突变型的NSCLCs。Phase

Dacomitinib hat mehrere klinische Phase-III-Studien durchlaufen und wurde im August 2018 in den USA und in Europa von Pfizer zur Zulassung eingereicht. Von der FDA wurde Dacomitinib im September 2018 in der Indikation NSCLC zugelassen. Seit April 2019

1/8/2018 · Purpose ARCHER 1050, a randomized, open-label, phase III study of dacomitinib versus gefitinib in treatment-naïve patients with advanced non-small-cell lung cancer (NSCLC) and activating mutations in EGFR, reported significant improvement in progression-free

1/8/2018 · Purpose ARCHER 1050, a randomized, open-label, phase III study of dacomitinib versus gefitinib in treatment-naïve patients with advanced non-small-cell lung cancer (NSCLC) and activating mutations in EGFR, reported significant improvement in progression-free

The active substance in Vizimpro, dacomitinib, belongs to a group of cancer medicine called tyrosine kinase inhibitor. It blocks the activity of EGFR, which normally controls growth and division of cells. In lung cancer cells, EGFR is often overactive, causing

1)Dacomitinib versus gefitinib for the first-line treatment of advanced EGFR mutation positive non-small cell lung cancer (ARCHER 1050): A randomized, open-label phase III trial.

Dacomitinib is an irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor which has activity against EGFR/HER1, HER2, and HER4, as well as some EGFR-activating mutations (exon 19 deletion or exon 21 L858R substitution mutation

Dacomitinib dose reductions for a maximum of two dose levels were permitted for treatment-related toxicity in the case of grade 3 or worse toxicity, or prolonged grade 2 adverse events lasting more than one cycle. The first dose reduction was to 30 mg/day and

Dacomitinib verlängerte den primären Endpunkt, das mediane PFS von 9,2 auf 14,7 Monate (Hazard-Ratio 0,59, p < 0,0001). Die Kurven des PFS begann sich nach etwa 5 Monaten zu teilen, nach 24 Monaten lebten in der Dacomitinib-Gruppe 30,6% der

I have read with great interest the report of the ARCHER 1050 trial by Li-Yong Wu and colleagues.1 The findings showed the superiority of dacomitinib over gefitinib in terms of progression-free survival in patients with stage IIIB/IV non-small-cell lung cancer (NSCLC

6/6/2017 · “Dacomitinib should be considered as a new treatment option for first-line management of patients with advanced EGFR-mutated NSCLC,” said lead author Tony Mok, MD, professor and chair of the Department of Clinical Oncology at the Chinese University of Hong

 · PDF 檔案

dacomitinib live longer than people who take gefitinib. They also live longer before their disease gets worse. An indirect comparison suggests there is no difference between dacomitinib and afatinib in terms of how long people live or how long it is before their

Afatinib, sold under the brand name Gilotrif among others, is a medication used to treat non-small cell lung carcinoma (NSCLC).[1][2][3] It belongs to the tyrosine kinase inhibitor family of medications.[4] It is taken by mouth.[4] It is mainly used to treat cases of NSCLC that harbour mutations in the epidermal growth factor receptor

Medical uses ·

Dacomitinib (PF-00299804) is an experimental drug candidate under development by Pfizer for the treatment of non-small-cell lung carcinoma. It is a selective and irreversible inhibitor of EGFR. Dacomitinib has advanced to several Phase III clinical trials.

dacomitinib (Vizimpro®) is accepted for use within NHSScotland. Indication under review: as monotherapy, for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor

Dacomitinib (10 mg/kg/d by daily oral gavage) effectively inhibits the growth of HCC827 GFP xenografts. In contrast, HCC827 Del/T790M xenografts are resistant to Gefitinib, whereas Dacomitinib treatment is substantially more effective at inhibiting growth of this.

Drug Overview Dacomitinib is a small-molecule, irreversible inhibitor of HER1, HER2, and HER4, under development by Pfizer. Mutation or amplification of the HER gene is seen in several malignancies including lung, breast, gastric, head and neck, and colorectal

Dacomitinib comes as a tablet to take by mouth. It is usually taken once daily with or without food. Take dacomitinib at around the same time every day. Follow the directions on your prescription label carefully, and ask your doctor or pharmacist to explain any part

 · PDF 檔案

BRIEF REPORT EGFR T790M and C797S Mutations as Mechanisms of Acquired Resistance to Dacomitinib Yoshihisa Kobayashi, MD, PhD, Toshio Fujino, MD, Masaya Nishino, MD, Takamasa Koga, MD, Masato Chiba, MD, Yuichi Sesumi, MD, Shuta Ohara

Dacomitinib side effects will improve after therapy is complete. Dacomitinib side effects may be quite manageable. There are many options to minimize or prevent the side effects of dacomitinib. The following side effects are common (occurring in greater than 30

This release contains forward-looking information about VIZIMPRO® (dacomitinib) and an approval in the U.S. for the first-line treatment of patients with metastatic NSCLC with EGFR exon 19 deletion or exon 21 L858R substitution mutations as detected by an

【港安药品导读】近日,FDA已受理达克替尼(Dacomitinib)的新药申请,用于携带EGFR激活突变的局部晚期或转移性非小细胞肺癌(NSCLC)患者的一线治疗,FDA针对此次申请授予了优先审查资格。此外,欧洲药品管理局也受理了该药的一份上市申请。

 · PDF 檔案

HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use VIZIMPRO safely and effectively. See full p rescribing information for VIZIMPRO. VIZIMPRO ® (dacomitinib) tablets, for oral use Initial U.S. Approval